Trametinib is a targeted therapy drug specifically classified as a MEK inhibitor. MEK, or Mitogen-activated protein kinase kinase, is a part of the MAPK/ERK pathway, which is often involved in the development and progression of cancer. By inhibiting MEK, trametinib helps to disrupt this pathway, thereby impeding cancer cell growth and proliferation.
